Posted by Michael Wonder on 15 May 2020
Neuraptive Therapeutics announces FDA has granted fast track designation to NTX-001 clinical development program for treatment of patients with peripheral nerve injuries
14 May 2020 - Neuraptive Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its franchise therapeutic product, NTX-001, in the treatment of patients with peripheral nerve injuries.
The company believes NTX-001 has the potential to improve the quality and speed of recovery of nerve sensation and function for eligible patients who have sustained traumatic injuries or who are undergoing reconstructive surgical procedures.
